Ligand Pharmaceuticals Inc
NASDAQ:LGND

Watchlist Manager
Ligand Pharmaceuticals Inc Logo
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Watchlist
Price: 116.65 USD 1.75% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Ligand Pharmaceuticals Inc?
Write Note

Ligand Pharmaceuticals Inc
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ligand Pharmaceuticals Inc
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Cash Taxes Paid
$26.1m
CAGR 3-Years
92%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Taxes Paid
$1.6B
CAGR 3-Years
47%
CAGR 5-Years
129%
CAGR 10-Years
84%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ligand Pharmaceuticals Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

In the bustling world of pharmaceuticals, Ligand Pharmaceuticals Inc. carves a distinct niche for itself as a company that thrives not on direct consumer market engagements but through the engines of innovation and strategic collaboration. Founded in 1987, Ligand has developed a business model centered around drug discovery and development technologies, as well as licensing these advancements to major pharmaceutical partners. Rather than manufacturing products directly for the consumer, Ligand's prowess lies in its proprietary technology platforms, such as Captisol, and its ability to monetize its intellectual properties through alliances. This allows Ligand to fuel a diverse pipeline of partnered products without bearing the risks and costs typically associated with late-stage drug development and commercialization. The company's financial ecosystem is further enriched by royalties, milestone payments, and licensing fees derived from over a hundred medications it has helped bring to market through its partnerships. By providing the technological backbone for novel therapies used in treating cancer, osteoporosis, fungal infections, and more, Ligand benefits financially when its partners succeed in commercializing drugs. This symbiotic model not only maximizes research and development efficiencies for Ligand but also positions the company as a crucial player in the value chain of the pharmaceutical industry. Their approach effectively balances innovation with financial prudence, enabling Ligand to focus on expanding its platform capabilities while diversifying its revenue streams.

LGND Intrinsic Value
82.48 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Ligand Pharmaceuticals Inc's Cash Taxes Paid?
Cash Taxes Paid
26.1m USD

Based on the financial report for Sep 30, 2024, Ligand Pharmaceuticals Inc's Cash Taxes Paid amounts to 26.1m USD.

What is Ligand Pharmaceuticals Inc's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
-23%

Over the last year, the Cash Taxes Paid growth was 422%. The average annual Cash Taxes Paid growth rates for Ligand Pharmaceuticals Inc have been 92% over the past three years , -23% over the past five years .

Back to Top